Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 8 Associations between ARM and maternal use of drugs against nausea and vomiting

From: Maternal drug use and the risk of anorectal malformations: systematic review and meta-analysis

  Maternal use of drugs against nausea and vomiting  
Ref. First author, year Exposure ORcrude [95% CI] ORadj [95% CI] Adjustment/matching factors
[49] Pasternak, 2013 Metoclopramide 0.7 [0.34, 1.54]c 0.8 [0.36, 1.66]b Matched and adjusted for hospitalization for hyperemesis gravidarum or nausea and vomiting, and use of other antiemetics in the first trimester
[78] Källén and Mottet, 2003 Meclozine 2.3 [0.99, 4.50]a
  1. aRisk Ratio (RR)
  2. bPrevalence odds ratio (POR)
  3. cNeuroleptics other than dixyrazine or prochloperazine